Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications.
Health Professionals
Neoadjuvant Immunotherapy Trial Sees High pCR Rates in Stage III Melanoma
A new study suggests a short course of immunotherapy before surgery may significantly improve outcomes in patients with high-risk melanoma.
Rosacea and melanoma strongly linked, big data says
Rosacea patients have more than five times the risk of developing a malignant melanoma and a greater risk of several other systemic conditions, according to researchers.
5-mm Margin May Be Enough for Excising Small Melanoma in Situ
Sun C, Lim A, De’Ambrosis B, et al. Recurrence Rate of Small Melanoma in Situ on Low-Risk Sites Excised With 5-mm Excisional Margin. JAMA Dermatol (2024).